Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141315 | 0.85 | DPP4 (0.63) | DPP4DPP8HSD11B1KDM4ELMNA | |
| SCHEMBL3149831 | 0.84 | DPP4 (0.61) | DPP4DPP8ALDH1A1LMNAKMT2A | |
| SCHEMBL3135795 | 0.82 | DPP4 (0.65) | DPP4DPP8HSD11B1 | |
| SCHEMBL29463863 | 0.82 | DPP4 (0.69) | DPP4DPP8LMNAHPGDKMT2A | |
| SCHEMBL3145122 | 0.82 | DPP4 (0.69) | DPP4DPP8LMNAHPGDKMT2A | |
| SCHEMBL3148993 | 0.81 | DPP4 (0.59) | DPP4DPP8KDM4EALDH1A1LMNA | |
| SCHEMBL3149470 | 0.81 | DPP4 (0.64) | DPP4DPP8KDM4EALDH1A1HPGD | |
| SCHEMBL3136513 | 0.81 | DPP4 (0.64) | DPP4DPP8HSD11B1KDM4EALDH1A1 | |
| SCHEMBL3145172 | 0.80 | DPP4 (0.61) | DPP4DPP8HSD11B1KDM4EALDH1A1 | |
| SCHEMBL3149850 | 0.79 | DPP4 (0.67) | DPP4DPP8KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753730-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | claimed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | claimed |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-08 | — | — | US | claimed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1753730-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | DPP4 2/4885DPP8 5/4885HSD11B1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.